ClinicalTrials.gg
TerminatedNCT05580770Updated Aug 20, 2026Results posted

Mirdametinib + BGB-3245 in Advanced Solid Tumors

A Phase 1/2 interventional study of Mirdametinib 2mg and BGB-3245 5mg in Advanced Solid Tumor, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Lack of tolerability of BGB-3245 (Brimarafenib) when given in combination with Mirdametinib

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate targeted therapy, or for which there is no treatment available, or prior standard of care therapy was not tolerated.

Read the detailed description

The study will be conducted in two sequential parts: Part 1 dose escalation (Phase 1) and Part 2 dose expansion (Phase 2a).

Participants will receive mirdametinib and brimarafenib administered by mouth every day on a continuous schedule. Mirdametinib will be dosed twice a day (BID) and brimarafenib will be dosed once a day (QD). One treatment cycle will be 28 days.

Part 1 of the study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary evidence of anti-tumor efficacy. Part 1 will also identify the MTD and the RP2D for the combination of mirdametinib with brimarafenib.

Part 2 will confirm the safety, tolerability, efficacy, PK, and PDx for the combination of mirdametinib and brimarafenib. It will follow a parallel design and include one or more dose expansion cohorts, where each participant would be treated with the combination of mirdametinib and brimarafenib at the RP2D. It will begin after the RP2D for the combination of mirdametinib and brimarafenib is identified in Part 1. Part 2 may start either in parallel with, or after, the conduct and analysis of the PDx Expansion Cohort in Part 1.

Participants who experience a TEAE requiring treatment modification will be managed according to the applicable guidelines in the protocol.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to provide
  • At least 18 years of age on day of signing ICF
  • Advanced, or unresectable solid cancer that has not responded to or progressed during or after at least 1 line of appropriate therapy or for which there is no treatment available or prior therapy was not tolerated.
  • Part 1: oncogenic mutation or other genomic aberration of the MAPK pathway
  • Part 2: oncogenic mutation or genomic aberration defined below:

    • Cohort A: cutaneous melanoma harboring NRAS mutations.
    • Cohort B: non-small cell lung cancer (NSCLC) harboring a KRAS mutation.
    • Cohort C: NSCLC or cutaneous melanoma harboring BRAF Class II or Class III mutations or BRAF Fusion mutation.
  • Must have or agree to a fresh tumor biopsy at screening
  • per 1.1
  • (ECOG) performance status of ≤ 2
  • Adequate organ function and no transfusion within 14 days of first dose

Key Exclusion Criteria:

  • Central Nervous System metastases, or untreated spinal cord compression
  • History of glaucoma
  • Active parathyroid disorder or history of associated hypercalcemia
  • cardiac disease within the past 6 months of signing ICF
  • History of toxicity from another RAF, MEK, ERK inhibitor requiring discontinuation of treatment from these agents
  • Severe or uncontrolled systemic disease
  • Inability to swallow oral medications
  • Clinically significant active infection (, or )
  • History of or ongoing Immune Thrombocytopenia (ITP), Von Willebrand disease and/or other past or present bleeding disorders
  • Underlying medical conditions in investigator's opinion to be unfavorable to be a part of the study
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose or anticipates need for major surgery while on study
  • Systemic anti-cancer therapy within 2 weeks or 5 half-lives before first dose
  • Concomitant systemic or therapy within 2 weeks before first dose
  • Concomitant medicines that are strong inhibitors or inducers within 2 weeks or 5 half-lives before first dose
  • within 4 weeks before first dose
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Phase 1 Dose Escalation, Cohort 1

    Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway

    Drug: Mirdametinib 2mg · Drug: BGB-3245 5mg

  • Experimental
    Phase 1 Dose Escalation, Cohort 2

    Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway

    Drug: Mirdametinib 2mg · Drug: BGB-3245 10mg

  • Experimental
    Phase 1 Dose Escalation, Cohort 3

    Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway

    Drug: Mirdametinib 2mg · Drug: BGB-3245 20mg

  • Experimental
    Phase 1 Dose Escalation, Cohort 4

    Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway

    Drug: Mirdametinib 3mg · Drug: BGB-3245 10mg

  • Experimental
    Phase 1 Dose Escalation, Cohort 5

    Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway

    Drug: Mirdametinib 4mg · Drug: BGB-3245 10mg

Interventions

  • Mirdametinib 2mg administered orally

    Also known as: PD-0325901

  • BGB-3245 5mg administered orally

    Also known as: Brimarafenib

  • Mirdametinib 3mg administered orally

    Also known as: PD-0325901

  • Mirdametinib 4mg administered orally

    Also known as: PD-0325901

  • BGB-3245 10mg administered orally

    Also known as: Brimarafenib

  • BGB-3245 20mg administered orally

    Also known as: Brimarafenib

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events

    Safety and tolerability endpoint evaluation via incidence of treatment emergent Adverse Events (TEAEs). TEAE severities were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. AEs were coded using MedDRA Version 27.1.

    Time frame: All adverse events were collected from the time of signing ICF until 30 days after the last dose of study treatment (an average of 3.48 months and up to 16.76 months).

  2. Maximum Tolerated Dose (Part 1 Only)

    The maximum tolerated dose (MTD) for mirdametinib and BGB-3245 administered as a combination, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1.

    Time frame: Up to 18 months

  3. Recommended Phase 2 Dose [RP2D] (Part 1 Only)

    The recommended phase 2 dose (RP2D) for mirdametinib and BGB-3245 administered as a combination will be determined based on safety, tolerability, PK, preliminary anti-tumor efficacy, and other available data.

    Time frame: Up to 24 months

  4. Objective Response Rate (Part 2 Only)

    Preliminary anti-tumor efficacy for the RP2D of mirdametinib and BGB-3245 administered as a combination as assessed by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). Objective Response Rate (ORR) defined as the proportion of participants with complete response (CR) + partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective Response Rate (Part 1 Only)

    Preliminary anti-tumor efficacy of mirdametinib and BGB-3245 administered as a combination as assessed by CT or MRI. ORR defined as the proportion of participants with Complete Response (CR) + Partial Response (PR) using RECIST v1.1. Responses were as reported by the investigators.

    Time frame: From participants' date of first dose of study treatment through end of treatment, an average of 3.5 months

  2. Duration of Response Rate

    Duration of response rate in participants treated with the combination of mirdametinib and BGB-3245, defined as the time from response (CR + PR using RECIST v1.1) to disease progression and/or death.

    Time frame: Up to 36 months

  3. Change in Plasma Concentrations of Mirdametinib and BGB-3245

    To determine the PK of mirdametinib and BGB-3245 administered as a combination in the eligible participant population. Plasma concentrations of mirdametinib and BGB-3245 will be measured to evaluate systemic exposures (AUC, Cmax, Ctrough, and other PK parameters as data allow).

    Time frame: Up to 24 months

07

Results

Posted May 1, 2026

Participant flow

Participants were enrolled in each Part 1 cohort following safety committee review. Study was terminated after Part 1 Cohort 5 was completed due to intolerance of the combination and no apparent early signs of efficacy. No participants were enrolled in Part 2 of the study.

Participant flow — Overall Study
MilestonePhase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose Escalation
Started37643
Completed33131
Not completed04512
Withdrew: Adverse event01402
Withdrew: Removal from study02010
Withdrew: Withdrawal by subject01100

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Events

Safety and tolerability endpoint evaluation via incidence of treatment emergent Adverse Events (TEAEs). TEAE severities were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. AEs were coded using MedDRA Version 27.1.

Time frame:
All adverse events were collected from the time of signing ICF until 30 days after the last dose of study treatment (an average of 3.48 months and up to 16.76 months).
Reported as:
Count of participants · Participants
Incidence of Treatment Emergent Adverse Events
ParticipantsPhase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationPhase 1 Overall - Dose Escalation
With at least one TEAE3764323
With at least one treatment-emergent SAE2353316
With at least one study procedure related TEAE010001
With at least one TEAE leading to any treatment discontinuation0242311
With at least one TEAE related to Mirdametinib2654320
With at least one TEAE related to BGB-32453654321
With at least one TEAE leading to Mirdametinib dose reduction121105
With at least one TEAE leading to BGB-3245 dose reduction021104
With at least one TEAE leading to Mirdametinib dose interruption2252213
With at least one TEAE leading to BGB-3245 dose interruption2352214
With a TEAE leading to discontinuation of Mirdametinib0241310
With a TEAE leading to discontinuation of BGB-32450142310
With at least one Mirdametinib treatment-emergent AE of special interest033219
With at least one BGB-3245 treatment-emergent AE of special interest0342110
PrimaryMaximum Tolerated Dose (Part 1 Only)

The maximum tolerated dose (MTD) for mirdametinib and BGB-3245 administered as a combination, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1.

Time frame:
Up to 18 months
Reported as:
Number · mg
Maximum Tolerated Dose (Part 1 Only)
mgPhase 1 Overall - Dose Escalation
Maximum Tolerated Dose: BGB-3245 (QD) when given in combination with mirdametinib10
Maximum Tolerated Dose: Mirdametinib (BID) when given in combination with BGB-32453
PrimaryRecommended Phase 2 Dose [RP2D] (Part 1 Only)

The recommended phase 2 dose (RP2D) for mirdametinib and BGB-3245 administered as a combination will be determined based on safety, tolerability, PK, preliminary anti-tumor efficacy, and other available data.

Time frame:
Up to 24 months
Reported as:
Count of participants · Participants
Recommended Phase 2 Dose [RP2D] (Part 1 Only)
ParticipantsPhase 1 Overall - Dose Escalation
Recommended Phase 2 Dose [RP2D] (Part 1 Only)NA
PrimaryObjective Response Rate (Part 2 Only)

Preliminary anti-tumor efficacy for the RP2D of mirdametinib and BGB-3245 administered as a combination as assessed by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). Objective Response Rate (ORR) defined as the proportion of participants with complete response (CR) + partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Time frame:
Up to 24 months

No measurements were reported for this outcome.

SecondaryObjective Response Rate (Part 1 Only)

Preliminary anti-tumor efficacy of mirdametinib and BGB-3245 administered as a combination as assessed by CT or MRI. ORR defined as the proportion of participants with Complete Response (CR) + Partial Response (PR) using RECIST v1.1. Responses were as reported by the investigators.

Time frame:
From participants' date of first dose of study treatment through end of treatment, an average of 3.5 months
Reported as:
Count of participants · Participants
Objective Response Rate (Part 1 Only)
ParticipantsPhase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationPhase 1 Overall - Dose Escalation
Objective Response Rate (Part 1 Only)000000
SecondaryDuration of Response Rate

Duration of response rate in participants treated with the combination of mirdametinib and BGB-3245, defined as the time from response (CR + PR using RECIST v1.1) to disease progression and/or death.

Time frame:
Up to 36 months

No measurements were reported for this outcome.

SecondaryChange in Plasma Concentrations of Mirdametinib and BGB-3245

To determine the PK of mirdametinib and BGB-3245 administered as a combination in the eligible participant population. Plasma concentrations of mirdametinib and BGB-3245 will be measured to evaluate systemic exposures (AUC, Cmax, Ctrough, and other PK parameters as data allow).

Time frame:
Up to 24 months
Reported as:
Mean · ng/mL
Change in Plasma Concentrations of Mirdametinib and BGB-3245
ng/mLPhase 1 Dose Escalation, Cohort 1Phase 1 Dose Escalation, Cohort 2Phase 1 Dose Escalation, Cohort 3Phase 1 Dose Escalation, Cohort 4Phase 1 Dose Escalation, Cohort 5
BGB-3245 Cycle 1 Day 1 -Predose0.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
BGB-3245 Cycle 1 Day 1-1 hr61.9 ± 38.6476.9 ± 79.50110.7 ± 70.99139.9 ± 61.83100.1 ± 15.49
BGB-3245 Cycle 1 Day 1-2 hr74.9 ± 16.62118.3 ± 79.66321.2 ± 113.73172.3 ± 42.62186.0 ± 26.87
BGB-3245 Cycle 1 Day 1-4 hr54.2 ± 7.98100.8 ± 53.88325.2 ± 96.65166.0 ± 102.81166.5 ± 14.85
BGB-3245 Cycle 1 Day 22- Predose518.0 ± 293.09404.7 ± 189.471675.0 ± 601.04541.0 ± 322.44—
BGB-3245 Cycle 2 Day 1 - Predose361.7 ± 334.31353.8 ± 160.651300.0 ± 84.85486.3 ± 232.15—
BGB-3245 Cycle 2 Day 1 - 1 hr436.0 ± 370.99498.2 ± 276.511350.0 ± 70.71558.7 ± 307.00—
BGB-3245 Cycle 2 Day 1 - 2 hr377.3 ± 343.60501.8 ± 374.161325.0 ± 162.63606.3 ± 341.03—
BGB-3245 Cycle 2 Day 1 - 4 hr305.7 ± 195.88365.8 ± 257.111225.0 ± 190.92406.0 ± 163.72—
BGB-3245 Cycle 3 Day 1 -Predose596.3 ± 393.52277.6 ± 271.991051.0 ± 281.439.1—
Mirdametinib Cycle 1 Day 1- Predose0.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
Mirdametinib Cycle 1 Day 1- 1 hr82.9 ± 8.0648.0 ± 24.7559.9 ± 25.01115.4 ± 44.31163.5 ± 40.31
Mirdametinib Cycle 1 Day 1- 2 hr39.2 ± 14.9634.8 ± 14.7336.6 ± 9.2848.0 ± 12.3464.6 ± 14.28
Mirdametinib Cycle 1 Day 1- 4 hr18.2 ± 7.0414.0 ± 4.3213.6 ± 3.0424.9 ± 5.5923.6 ± 3.46
Mirdametinib Cycle 1 Day 22- Predose35.4 ± 2.9315.7 ± 7.1813.0 ± 4.1738.9 ± 11.88—
Mirdametinib Cycle 2 Day 1- Predose19.2 ± 16.8610.9 ± 7.3313.1 ± 2.4028.9 ± 3.74—
Mirdametinib Cycle 2 Day 1- 1 hr90.1 ± 66.5081.5 ± 72.1548.0 ± 21.78143.0 ± 14.42—
Mirdametinib Cycle 2 Day 1- 2 hr56.8 ± 18.8646.9 ± 27.2562.0 ± 41.51100.4 ± 2.95—
Mirdametinib Cycle 2 Day 1- 4 hr36.2 ± 15.7926.2 ± 11.3824.1 ± 7.0052.0 ± 8.64—
Mirdametinib Cycle 3 Day 1- Predose23.8 ± 13.6010.3 ± 11.119.2 ± 4.060 ± 0.00—

Adverse events

Collected over All SAEs and AEs were collected from the time of signing ICF until 30 days after the last dose of study treatment (an average of 3.48 months and up to 16.76 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1, Cohort 1 - Dose Escalation0/3 (0%)2/3 (66.7%)3/3 (100%)
Phase 1, Cohort 2 - Dose Escalation1/7 (14.3%)3/7 (42.9%)7/7 (100%)
Phase 1, Cohort 3 - Dose Escalation0/6 (0%)5/6 (83.3%)5/6 (83.3%)
Phase 1, Cohort 4 - Dose Escalation1/4 (25%)3/4 (75%)4/4 (100%)
Phase 1, Cohort 5 - Dose Escalation1/3 (33.3%)3/3 (100%)3/3 (100%)
Phase 1 Overall3/23 (13%)16/23 (69.6%)22/23 (95.7%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPhase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationPhase 1 Overall
SepsisInfections and infestations0/30/70/60/41/31/23
PyrexiaGeneral disorders1/30/72/60/41/34/23
Abdominal painGastrointestinal disorders0/31/70/60/41/32/23
DehydrationMetabolism and nutrition disorders1/30/70/60/40/31/23
DyspnoeaRespiratory, thoracic and mediastinal disorders1/30/70/60/40/31/23
Rash maculo-papularSkin and subcutaneous tissue disorders0/30/70/60/41/31/23
Sinus tachycardiaCardiac disorders0/30/70/60/41/31/23
MalnutritionMetabolism and nutrition disorders0/30/70/61/40/31/23
Confusional statePsychiatric disorders0/30/70/61/40/31/23
DeliriumPsychiatric disorders0/30/70/61/40/31/23
Most frequent other events
Showing 10 of 52
Most frequent other events
EventPhase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationPhase 1 Overall
DiarrhoeaGastrointestinal disorders1/33/72/64/42/312/23
Dermatitis acneiformSkin and subcutaneous tissue disorders3/31/71/62/41/38/23
NauseaGastrointestinal disorders1/33/72/63/42/311/23
VomitingGastrointestinal disorders0/32/72/63/40/37/23
FatigueGeneral disorders2/35/72/61/42/312/23
HypoalbuminaemiaMetabolism and nutrition disorders2/30/71/61/40/34/23
Blood creatine phosphokinase increasedInvestigations2/33/74/61/41/311/23
Aspartate aminotransferase increasedInvestigations2/30/71/62/41/36/23
Blood creatinine increasedInvestigations2/31/70/60/40/33/23
HeadacheNervous system disorders0/34/71/61/40/36/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationTotal
Median72 (62.0 to 72.0)56 (49.0 to 64.0)54 (49.0 to 72.0)52 (50.5 to 54.5)41 (39.0 to 60.0)55 (49.0 to 64.0)
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationTotal
Female1613213
Male2151110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationTotal
Hispanic or Latino000000
Not Hispanic or Latino3654119
Unknown or Not Reported011024
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationTotal
American Indian or Alaska Native000000
Asian001001
Native Hawaiian or Other Pacific Islander000000
Black or African American021003
White3523114
More than one race000000
Unknown or Not Reported002125
Region of Enrollment
Region of Enrollment(participants)Phase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationTotal
United States3453116
Australia031127
Type of Cancer Diagnosis
Type of Cancer Diagnosis(Participants)Phase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationTotal
Non-small Cell Lung Carcinoma010001
Colorectal Cancer002114
Ovarian Cancer010012
Melanoma232119
Pancreatic Cancer101002
Other021205
Time Since Initial Diagnosis
Time Since Initial Diagnosis(months)Phase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationTotal
Median100.3 (29.2 to 187.9)63.1 (46.4 to 139.2)33.0 (26.6 to 103.2)14.9 (7.5 to 60.7)68.8 (68.8 to 68.8)60.2 (26.6 to 100.3)
Time Since First Metastatic Disease
Time Since First Metastatic Disease(months)Phase 1, Cohort 1 - Dose EscalationPhase 1, Cohort 2 - Dose EscalationPhase 1, Cohort 3 - Dose EscalationPhase 1, Cohort 4 - Dose EscalationPhase 1, Cohort 5 - Dose EscalationTotal
Median68.3 (14.7 to 108.9)56.3 (24.6 to 60.2)36.1 (28.9 to 84.1)7.0 (6.4 to 52.8)79.3 (68.8 to 89.8)56.3 (24.6 to 68.8)

7 further baseline measures are reported on the registry.

08

Study locations

8 sites
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
  • Yale-New Haven Hospital-Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Calvary Mater Newcastle
    Waratah, 2298, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD supporting publicly available results will be evaluated for sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: IPD from completed trials will be publicly available within 6 months after all of the following events: Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions Public results via primary manuscript or trial registry disclosure Legal authority to share data Privacy protections are in place If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21

Access criteria: Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Jan 2025, 23 months.

Results were first posted in May 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2022
First posted
Oct 14, 2022
StartActual
Feb 3, 2023
Primary completionActual
Jan 15, 2025
CompletionActual
Jan 15, 2025
Results first posted
May 1, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05580770
Responsible party
Sponsor
First posted
Oct 14, 2022
Start date
Feb 3, 2023
Primary completion
Jan 15, 2025
Completion
Jan 15, 2025
Results posted
May 1, 2026
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mirdametinib · Brimarafenib

Start the discussion